Kineta Inc. is a biopharmaceutical company specializing in the development of first-in-class novel immunotherapies aimed at transforming patient lives. The company focuses on advancing treatments from discovery to proof of concept, particularly in the fields of immuno-oncology and neuroscience. Kineta serves patients suffering from cancer and chronic pain, addressing a significant gap in the biopharmaceutical industry by reprogramming the immune system to target and kill cancer cells and developing non-opioid treatments for chronic pain.

Kineta operates in the highly competitive biopharmaceutical market, targeting healthcare providers, research institutions, and pharmaceutical companies as its primary clients. The business model revolves around early-stage drug development, securing funding through investment rounds, and forming strategic partnerships for clinical trials and commercialization. Revenue is generated through licensing agreements, milestone payments, and royalties from successful drug candidates.

Keywords: immunotherapies, cancer treatment, chronic pain, biopharmaceutical, drug development, immuno-oncology, neuroscience, non-opioid, investment, partnerships.